Antitumor activity of dual-specific T cells and influenza virus

[1]  M. Smyth,et al.  Supernatural T cells: genetic modification of T cells for cancer therapy , 2005, Nature Reviews Immunology.

[2]  F. Thistlethwaite,et al.  Engineering T cells for cancer therapy , 2005, British Journal of Cancer.

[3]  Michel Sadelain,et al.  Targeted elimination of prostate cancer by genetically directed human T lymphocytes. , 2005, Cancer research.

[4]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[5]  S. Rosenberg,et al.  Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression , 2005, Journal of immunotherapy.

[6]  P. Stern,et al.  The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens , 2005, Journal of immunotherapy.

[7]  R. Herrmann,et al.  Overview of monoclonal antibodies in cancer therapy: present and promise. , 2005, Critical reviews in oncology/hematology.

[8]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  David D. Smith,et al.  Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. , 2005, Blood.

[10]  S. Rosenberg,et al.  Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred , 2022 .

[11]  S. Forman,et al.  Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells , 2004, Cancer Research.

[12]  Z. Eshhar,et al.  Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. , 2004, The Journal of clinical investigation.

[13]  M. Smyth,et al.  Cytokines in cancer immunity and immunotherapy , 2004, Immunological reviews.

[14]  A. Boynton,et al.  Anti‐prostate specific membrane antigen designer T cells for prostate cancer therapy , 2004, The Prostate.

[15]  M. Brenner,et al.  Genetic modification of T lymphocytes for adoptive immunotherapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  M. Harris.  Monoclonal antibodies as therapeutic agents for cancer. , 2004, The Lancet. Oncology.

[17]  R. Hagedoorn,et al.  Reprogramming of Virus-specific T Cells into Leukemia-reactive T Cells Using T Cell Receptor Gene Transfer , 2004, The Journal of experimental medicine.

[18]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[19]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[20]  J. Blattman,et al.  Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. , 2003, Cancer cell.

[21]  P. Hwu,et al.  Dual-specific T cells combine proliferation and antitumor activity , 2002, Nature Biotechnology.

[22]  J. Trapani,et al.  Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. , 2002, Blood.

[23]  L. Brown,et al.  Induction of Long-Term Memory CD8+ T Cells for Recall of Viral Clearing Responses against Influenza Virus , 2002, Journal of Virology.

[24]  C. Rooney,et al.  Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. , 2002, Blood.

[25]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[26]  P. Doherty,et al.  Measuring the diaspora for virus-specific CD8+ T cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Robinson,et al.  Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity1 , 2000, The Journal of Immunology.

[28]  J. Trapani,et al.  Redirected Perforin-Dependent Lysis of Colon Carcinoma by Ex Vivo Genetically Engineered CTL1 , 2000, The Journal of Immunology.

[29]  J. Mcarthur,et al.  Impact of chimeric immune receptor extracellular protein domains on T cell function , 1999, Gene Therapy.

[30]  B. Robinson,et al.  T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. , 1999, Cancer research.

[31]  B. Groner,et al.  A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. , 1995, Gene therapy.

[32]  P. Doherty,et al.  CD8+ T-cell memory to viruses. , 1994, Current opinion in immunology.

[33]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[34]  V. Koppaka,et al.  anti* , 2002, Annals of Internal Medicine.